牛皮并发症与多质神炎成功地用Ixekizumab治疗:一个病例报告
1Department of Dermatology, Hangzhou Third People's Hospital, Hangzhou, Zhejiang Province, China.
Medicine
|May 29, 2025
概括
这个案例研究突出了一个患有牛皮和多质神炎的患者. 伊克西祖马布有效地治疗了这两种疾病,解决了皮肤皮疹,并使肌酸激酶水平正常化,与ETANERCEPT不同,肌肉炎恶化.
科学领域:
- 皮肤病学 皮肤病学
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
背景情况:
- 牛皮是一种慢性炎症性皮肤疾病.
- 多质炎是牛皮的罕见并发症.
- 治疗牛皮的Etanercept可能会导致肌肉炎的恶化.
研究的目的:
- 报告与多质神炎相关的牛皮病例.
- 为了评估Ixekizumab在治疗复杂的多质神炎导致的牛皮的疗效.
- 为了比较Etanercept和Ixekizumab在治疗牛皮和肌肉炎中的作用.
主要方法:
- 一名被诊断患有牛皮和肌肉炎的22岁女性接受了Etanercept治疗,导致肌酸激酶 (CK) 水平升高.
- 随后,该患者接受了甲基prednisolone,甲醇和ixekizumab的联合治疗.
- 在整个治疗过程中,监测疾病活性和CK水平.
主要成果:
- 埃坦尼塞普特治疗最初恶化了肌肉炎,由增加的CK水平表明.
- 结合甲基prednisolone,甲基和ixekizumab的联合治疗导致了牛皮皮疹的完全消失.
- 在Ixekizumab治疗后,血清CK水平恢复正常.
结论:
- 在患有牛皮和多重牛皮的患者中,etanercept可能会加重肌肉炎.
- 伊克西祖马布在治疗由多质神炎复杂化的牛皮方面表现出有效性.
- 这一案例表明,Ixekizumab是这种复杂病例的可行治疗选择.
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
143
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
143
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
117
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
117
01:21EPS and iPS Cells in Disease Research
2.8K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
2.8K
01:29Inflammatory Bowel Disease IV: Pharmacological Management
118
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
118
01:22iPS Cell Differentiation
2.6K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.6K
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
97
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
97